Answers are grounded in this paper and cite their sources.
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
No takes yet. Share an insight, caveat, or question.
Rappuoli et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: